Abstract
This article reviews the findings of Wu et al. on the risk of malignancy in psoriasis patients treated with long-term TNF-α inhibitors (TNFi). While the study found no significant increase in the risk of most cancers, it highlighted a higher risk of non-melanoma skin cancers, particularly squamous cell carcinoma, in patients with psoriatic arthritis. The article discusses the clinical implications for psoriasis patients with a history of malignancy, advocating for a personalised treatment approach, vigilant monitoring, and the need for further research to better understand the relationship between biologic therapy and cancer recurrence.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call